Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ROS1 status confers therapeutic sensitivity to Repotrectinib in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
This statement is based on a regulatory approval from the Food and Drug Administration:
AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).